Amal A. Abbas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amal A. Abbas has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Doaa Zakaria
Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Abbassia Square, P.O. Box 11566, Cairo, Egypt
1 shared publicationHala Ghareeb
Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Abbassia Square, P.O. Box 11566, Cairo, Egypt
1 shared publicationMai Mohammed
Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Abbassia Square, P.O. Box 11566, Cairo, Egypt
1 shared publicationRanda Reda
Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Abbassia Square, P.O. Box 11566, Cairo, Egypt
1 shared publication- Rania Ahmed Abo-Shady
Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
1 shared publication Rania H. El Kabarity
Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Abbassia Square, P.O. Box 11566, Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
- 4 October 2015
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2015, 1-11
The Interplay between Zinc, Vitamin D and, IL-17 in Patients with Chronic Hepatitis C Liver Disease
Objectives. To assess zinc (Zn) and vitamin D (Vit. D) status in chronic Hepatitis C virus- (HCV) infected patients and their relationship to interleukin- (IL-) 17 and disease severity and then investigate whether Zn and Vit. D3 modulate IL-17 expression in chronic HCV patients.Methods. Seventy patients and fifty healthy subjects were investigated. Serum levels of Zn, Vit. D, and IL-17 were assessed in the patients group and subgroups. Patients lymphocytes were activatedin vitroin the presence or absence of Zn or Vit. D3 and then intracellular IL-17 production was assessed using flow cytometry.Results. Zn and Vit. D were significantly decreased in HCV patients. Increasing disease severity leads to more reduction in Zn level opposed by increasing IL-17 level. Zn potently reduced IL-17 production in a dose-related fashion; however it did not exert any toxic effects. Although Vit. D apparently increases IL17 expression, it is unclear whether it is due to its toxic effect on cell count or lack of definite association between Vit. D and both IL-17 and disease severity.Conclusions. This study demonstrates that Zn modulates IL-17 expression and provides a rationale for evaluating this compound as a supplementary agent in the treatment of chronic HCV.
- 4 October 2015
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2015, 1-11
Open AccessThe Interplay between Zinc, Vitamin D and, IL-17 in Patients with Chronic Hepatitis C Liver Disease
Objectives. To assess zinc (Zn) and vitamin D (Vit. D) status in chronic Hepatitis C virus- (HCV) infected patients and their relationship to interleukin- (IL-) 17 and disease severity and then investigate whether Zn and Vit. D3 modulate IL-17 expression in chronic HCV patients.Methods. Seventy patients and fifty healthy subjects were investigated. Serum levels of Zn, Vit. D, and IL-17 were assessed in the patients group and subgroups. Patients lymphocytes were activatedin vitroin the presence or absence of Zn or Vit. D3 and then intracellular IL-17 production was assessed using flow cytometry.Results. Zn and Vit. D were significantly decreased in HCV patients. Increasing disease severity leads to more reduction in Zn level opposed by increasing IL-17 level. Zn potently reduced IL-17 production in a dose-related fashion; however it did not exert any toxic effects. Although Vit. D apparently increases IL17 expression, it is unclear whether it is due to its toxic effect on cell count or lack of definite association between Vit. D and both IL-17 and disease severity.Conclusions. This study demonstrates that Zn modulates IL-17 expression and provides a rationale for evaluating this compound as a supplementary agent in the treatment of chronic HCV.